Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...

Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...

The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...

Why have BMS investors been anything but positive about acquiring 2seventy? The answer stems from uncertainty over how competitive Abecma will continue to be in the multiple myeloma space given an ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight ...

More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

Fintel reports that on March 11, 2025, Leerink Partners downgraded their outlook for 2seventy bio (NasdaqGS:TSVT) from ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

Morgan Stanley lowered the firm’s price target on 2seventy Bio (TSVT) to $5 from $6 and keeps an Equal Weight rating on the shares following ...

CAMBRIDGE, Mass., March 11, 2025--2seventy bio, Inc. (Nasdaq: TSVT), today announced a definitive merger agreement under ...

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...